|
February 6, 2020 (Thursday) |
10:00 hrs
|
Welcome Address
Shri. Pankaj R. Patel
Chief Patron
The Ramanbhai Foundation, 9th International Symposium
|
10.10 hrs
|
Lighting of the lamp
|
10.15 hrs |
Introduction to the keynote speaker
Sharvil P. Patel, Ph.D
Managing Director, Zydus Cadila |
10.25 hrs |
|
Inaugural Key Note Address
“Global Health R&D Priorities”
Marie-Paule Kieny, PhD
Chair of the Board, Drugs for Neglected Diseases Initiative (DNDi, Geneva, Switzerland)
Medicines Patent Pool Foundation (MPPF, Geneva, Switzerland)
Director of Research at INSERM, France
Vice-Chair of the Board of the Global Antibiotic Research and Development Partnership (GARDP, Geneva, Switzerland)
Member of the Board of Directors of the Human Vaccine Project (HVP, New York, USA)
Former Assistant Director-General for Health Systems and Innovation at the World Health Organization (WHO)
|
11.25 hrs |
Vote of Thanks
Mr. Ganesh Nayak
COO & Executive Director, Zydus Cadila |
11:30 hrs |
Poster Session Inauguration
Sharvil P. Patel, Ph.D
Managing Director, Zydus Cadila
Tea Break |
Session I : Infectious and Neglected Diseases |
Chairpersons: |
Suman Rijal, Ph.D
Mukul Jain, Ph.D |
13:00 hrs |
|
“Rationale Development of Novel Combination treatments against Malaria”
Joerg Mohrle, Ph.D
Vice President, Head of Translational Medicine,
Research & Development,
Medicines for Malaria Venture |
13:30 hrs |
|
“Development of Bedaquiline and new drug discovery challenges for infectious diseases”
Anil Koul, Ph.D
Vice-President and Head,
Global Public Health and Infectious Diseases Discovery,
Johnson & Johnson
Format Director, CSIR - IMTECH |
14:00 hrs |
Lunch |
| 15:00 hrs |
 |
“Bolstering the TB Treatment Paradigm”
Shridhar Narayanan, Ph.D
Director
Foundation for Neglected Disease Research (FNDR) |
| 15:30 hrs |
 |
“Development of a Cocktail mAbs product for passive immunization against Rabies”
Sanjeev Kumar, Ph.D
President
Zydus Biologics |
| 16:00 hrs |
Tea-Break |
16:30 hrs |
ACS Five by Five session
- Five early-career researchers (shortlisted by ACS based on their abstract) will be allowed to present their research work on stage for five minutes using five slides.
- ACS will award a specific journal certificate and a one year ACS membership to these shortlisted participants.
|
17:30 hrs |
Wrap-up session |
| February 7, 2020 (Friday) |
09:00 hrs |
|
Key Note Address: “Year Gone By 2019 – Year Ahead 2020”
Naga Chalasani, MD, FACG
Associate Dean for Clinical Research and Director,
Division of Gastroenterology & Hepatology,
Indiana University School of Medicine |
09:30 hrs |
|
“Molecular Subclasses of NAFLD”
Arun Sanyal, MD
Professor of Medicine,
Physiology and Molecular Pathology,
Virginia Commonwealth University
|
10:00 hrs |
Tea-Break & Posters Session |
Session II : Clinical/Risk factors/Natural History Aspects of NAFLD/NASH |
Chairpersons: |
Arun Sanyal, MD
Y. K. Chawla, MD |
11:30 hrs |
|
“Heterogenicity of NAFLD Patients”
Akash Shukla, MD, DM
Head of Department of Gastroenterology
King Edward Memorial Hospital, Mumbai |
12:00 hrs |
|
“NAFLD in LEAN Individuals”
Abhijit Chowdhury, MD, DNB, DM
Professor & Head, Department of Hepatology,
Institute of Post Graduate Medical Education & Research, Kolkata
Institute of Post Graduate Medical Education & Research |
12:30 hrs |
|
“Sarcopenia & Frailty – Impact in NASH”
Kaushal Madan, MD, DNB, DM
Director of Gastroenterology & Hepatology Department,
Max Hospital, Gurgram
Max Hospital |
| 13:00 hrs |
 |
“Connection: CV & NASH”
Mohammad Siddiqui, MD
Associate Professor
Assistant Professor of Medicine
Department of Internal Medicine
Division of Gastroenterology, Hepatology and Nutrition Development,
Virginia Commonwealth University |
13:30 hrs |
Lunch |
| Chairpersons: |
Naga Chalasani, MD, FACG
Alok Dhavan, Ph.D |
14:30 hrs |
|
“STATE of ART: Placebo Response Considerations in NASH Clinical trials”
Mazer Noureddin, MD, MHSc
Director
Cedars-Sinai Fatty Liver Program |
15:00 hrs |
|
“Innovations In Clinical Trial Designs in NASH”
Arun Sanyal, MD
Professor of Medicine,
Physiology and Molecular Pathology,
Virginia Commonwealth University |
15:30 hrs |
|
“DILI in NAFLD”
Harshad Devarbhavi, MD, DM
Professor of Gastroenterology,
St. John's Medical College and Hospital, Bengaluru |
16:00 hrs |
Tea Break |
16:30 hrs |
PANEL DISCUSSION:
How Should I (Gastro/ Endo views) treat NAFLD/NASH in my clinic?
Moderator: Ajay Duseja
KT Shenoy, Krishnadas D, Banshi Saboo, Ketan Mehta |
17:15 hrs – 18.00 hours |
PANEL DISCUSSION:
Role of Social MEDIA in NASH AWARENESS
Moderator: Deven Parmar (Zydus Cadila)
Arun Sanyal, Naim Alkouri, Ketan Mehta, Ajay Duseja |
| February 8, 2020 (Saturday) |
Chairpersons:
|
Narayanswamy, MD |
09.00 hrs |
|
Key Note Address: “Genetic Modifiers of NAFLD & NASH”
Naga Chalasani, MD, FACG
Associate Dean for Clinical Research and Director,
Division of Gastroenterology & Hepatology,
Indiana University School of Medicine |
09:30 hrs |
|
Key Note Address: “Fecal Microbial Transplant: Challenges & Opportunities”
Dr. Shiv Sarin, MD, DM
Senior Professor and Head, Department of Hepatology Director,
Institute of Liver and Biliary Science (ILBS) |
Session III : Diagnostics |
Chairpersons: |
V. A. Saraswat, MD
Krishnadas, MD
Asita De Silva, MD
|
10:00 hrs |
|
“STATE OF ART: Current Non Invasive Diagnostic Modalities? Which is Best?”
Raj Vuppalanchi, MD
Associate Professor of Medicine,
Indiana University School of Medicine |
10:30 hrs |
|
“Role of Metabolomics in NASH Development”
Pablo Ortiz, MD, PhD
Chief Executive Officer,
OWL Metabolomics |
11:00 hrs |
|
“Qualification of noninvasive tests for routine use in the clinic for NASH”
Arun Sanyal, MD
Professor of Medicine,
Physiology and Molecular Pathology,
Virginia Commonwealth University |
11:20 hrs |
Tea-Break |
| Session IV: Advances in Pharmacotherapy - NASH |
Chairpersons:
|
Abraham Koshy, MD
Sanjay Maroo, MD
|
12:00 hrs |
|
“PPAR Biology & Novel applications for NASH”
Ajay Duseja, MD, DM
Department of Hepatology,
PGIMER, Chandigarh |
12:20 hrs |
|
“Skeletal Muscle - an overlooked link in the effective treatment for NAFLD/NASH”
Manu Chakravarthy, MD, PhD
Chief Medical Officer and Senior Vice President,
Clinical Development,
Axcella Health. |
| 12:40 hrs |
 |
“STATE of ART: Strategies For NASH Drug Development – Key takeaways”
Arun Sanyal, MD
Professor of Medicine,
Physiology and Molecular Pathology,
Virginia Commonwealth University |
13:00 hrs |
Lunch |
Session V: Tropic of Special Interest |
Chairpersons:
|
Sanjiv Saigal, MD
Ajay Duseja, MD
Nilay Mehta, MD |
14:00 hrs |
|
“STATE of ART: Implications of NASH cirrhosis on post LT clinical care”
Mohammad Siddiqui, MD
Associate Professor
Assistant Professor of Medicine
Department of Internal Medicine
Division of Gastroenterology, Hepatology and Nutrition Development,
Virginia Commonwealth University |
14:40 hrs |
|
“Paediatric NASH”
Naim Alkhouri, MD
Director of the Metabolic Health Center
Department of Internal Medicine
Texas Liver Institute, San Antonio |
15:00 hrs |
|
“Bariatric Surgery & NASH”
Raj Vuppalanchi, MD
Associate Professor of Medicine,
Indiana University School of Medicine |
15:20 hrs |
ACS : Five by Five
- Five early-career researchers (shortlisted by ACS based on their poster
presentation) will be allowed to present on stage for five minutes using five
slides.
- ACS will award a specific journal certificate and a one-year ACS membership to
these shortlisted participants.
|
16:00 hrs |
Vote of Thanks
Sharvil P. Patel, Ph.D
Managing Director, Zydus Cadila |
| 16:10 hrs |
Tea |
|
|
